(6R)-tetrahydrofolic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 英文名称: (6R)-tetrahydrofolic acid
• 英文别名: 2-[[4-[[(6R)-2-amino-4-oxo-5,6,7,8-tetrahydro-3H-pteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid
• 化学式: C₁₉H₂₃N₇O₆
• 分子量: 445.435
• InChiKey: MSTNYGQPCMXVAQ-JHJMLUEUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  32
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  207
• 氢给体数：
  8
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  (6R)-tetrahydrofolic acid 生成 calcium salt of (6R)-tetrahydrofolic acid
  参考文献：
  名称：

  Stable crystalline tetrahydrofolic acid salts

  摘要：

  本发明涉及(6R,S)-、(6S)-和(6R)-四氢叶酸的稳定晶体盐，以及制备这些盐的方法和它们作为药物和制药制剂生产成分的用途。

  公开号：

  US05817659A1

文献信息

• [EN] FOLATE SALTS FOR MEDICAL USE<br/>[FR] SELS DE FOLATE À USAGE MÉDICAL
  申请人：APROFOL AG

  公开号：WO2019063236A1

  公开（公告）日：2019-04-04

  The invention relates to amorphous folate salt. The salt consists of a folate anion and an organic cation. The folate anion is selected from the group consisting of 5-formyl-(6S)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid, 5-methyl- (6S)-tetrahydrofolic acid, (6S)-tetrahydrofolic acid, 5,10-Methylene-(6R)- tetrahydrofolic acid, and its oxidized derivatives JK12A and Mefox, and the cation is an organic compound selected from the group arginine, choline, acetylcholine, 1,1-dimethyl-biguanidin phenylethylbiguanidin, betaine-methylester and dimethylanninoethanol. The cation is an organic compound with a complementary pharmacological activity.

  该发明涉及非晶态叶酸盐。该盐由叶酸阴离子和有机阳离子组成。叶酸阴离子选自5-甲酰-(6S)-四氢叶酸、10-甲酰-(6R)-四氢叶酸、5-甲基-(6S)-四氢叶酸、(6S)-四氢叶酸、5,10-亚甲基-(6R)-四氢叶酸及其氧化衍生物JK12A和Mefox等，阳离子选自精氨酸、胆碱、乙酰胆碱、1,1-二甲基-双胍苯乙双胍、甜菜碱甲酯和二甲基氨基乙醇等有机化合物。该阳离子是具有互补药理活性的有机化合物。
• FOLATES, COMPOSITIONS AND USES THEREOF
  申请人：Valoti Ermanno

  公开号：US20090209543A1

  公开（公告）日：2009-08-20

  The present invention relates to folates, compositions and uses thereof; In particular, this invention describes a crystalline or amorphous compound which is a substituted or unsubstituted folate or a reduced folate, or the natural or unnatural isomers thereof, of at least one organic base, as well as compositions and uses thereof. The compounds of the invention show a long lasting stability as well as a peculiarly high water-solubility.

  本发明涉及叶酸、其组合物和用途；具体而言，本发明描述了一种结晶或非晶化合物，该化合物是一种取代或未取代的叶酸或还原叶酸，或其至少一种有机碱的天然或非天然异构体，以及其组合物和用途。本发明的化合物表现出长期稳定性以及异常高的水溶性。
• [EN] FOLATES, COMPOSITIONS AND USES THEREOF<br/>[FR] FOLATES, COMPOSITIONS ET UTILISATIONS ASSOCIÉES
  申请人：GNOSIS SPA

  公开号：WO2009103334A1

  公开（公告）日：2009-08-27

  The present invention relates to folates, compositions and uses thereof; In particular, this invention describes a crystalline or amorphous compound which is a substituted or unsubstituted folate or a reduced folate, or the natural or unnatural isomers thereof, of at least one organic base, as well as compositions and uses thereof. The compounds of the invention show a long lasting stability as well as a peculiarly high water-solubility.

  本发明涉及叶酸、其组合物和用途；具体而言，本发明描述了一种晶体或非晶体化合物，该化合物是一种取代或未取代的叶酸或还原叶酸，或其天然或非天然异构体，至少含有一种有机碱基，以及其组合物和用途。本发明的化合物表现出长期稳定性以及特别高的水溶性。
• [EN] ISOMERICALLY PURE 18F-LABELLED TETRAHYDROFOLATES<br/>[FR] TÉTRAHYDROFOLATES ISOMÉRIQUEMENT PURS MARQUÉS AU 18F
  申请人：MERCK PATENT GMBH

  公开号：WO2018172243A1

  公开（公告）日：2018-09-27

  The present invention is directed towards isomerically pure 18F-labelled (6S)-or (6R)-5-methyltetrahydrofolate radiopharmaceuticals, wherein the phenyl group within the folate structure, has been replaced by an 18F-labelled N-heterocycle, for use in diagnostic imaging of a cell or population of cells expressing a folate-receptor in vitro or in vivo or for use in monitoring of cancer or inflammatory and autoimmune diseases and therapy thereof.

  本发明涉及具有异构纯的18F标记的（6S）-或（6R）-5-甲基四氢叶酸放射性药物，其中叶酸结构中的苯基被18F标记的N-杂环所取代，用于体外或体内诊断成像表达叶酸受体的细胞或细胞群，或用于癌症、炎症和自身免疫疾病的监测和治疗。
• [EN] RESOLUTION OF TETRAHYDROFOLIC ACID DERIVATIVES<br/>[FR] SÉPARATION DE DÉRIVÉS D'ACIDE TÉTRAHYDROFOLIQUE
  申请人：WATSON LAB INC

  公开号：WO2013025203A1

  公开（公告）日：2013-02-21

  A process of preparing (6S)-tetrahydrofolic acid derivatives comprising reacting racemic (6RS)-tetrahydrofolic acid derivatives with N-alkyl-D-glucamine, forming N-alkyl-D-glucamine salts of the (6RS)-tetrahydrofolic acid derivatives, isolation of the N-alkyl-D-glucamine salt of the (6S)-tetrahydrofolic acid derivative, removal of the N-alkyl-D-glucamine cation and purification of the (6S)-tetrahydrofolic acid derivative. The purified (6S)-tetrahydrofolic acid derivative can then be converted into the corresponding alkali metal or alkaline earth metal salts.

  制备（6S）-四氢叶酸衍生物的过程包括将外消旋（6RS）-四氢叶酸衍生物与N-烷基-D-葡糖胺反应，形成（6RS）-四氢叶酸衍生物的N-烷基-D-葡糖胺盐，分离出（6S）-四氢叶酸衍生物的N-烷基-D-葡糖胺盐，去除N-烷基-D-葡糖胺阳离子，并纯化（6S）-四氢叶酸衍生物。然后，纯化的（6S）-四氢叶酸衍生物可以转化为相应的碱金属或碱土金属盐。